Synonyms: CNTO-1275 | L04AC05 | Stelara® | TT-20
ustekinumab is an approved drug (FDA (2009), EMA (2009))
Compound class:
Antibody
Comment: Ustekinumab suppresses the immunomodulatory actions of both IL-12 and IL-23 on T-cell sub-populations. It binds to the common p40 subunit (IL12B) shared by these cytokines.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Qyuns Therapeutics have a potential ustekinumab biosimilar (QX001S) in Phase 1 evaluation for psoriasis (trial registry number ChiCTR1900022127). |
Classification ![]() |
|
Compound class | Antibody |
Approved drug? | Yes (FDA (2009), EMA (2009)) |
International Nonproprietary Names ![]() |
|
INN number | INN |
8954 | ustekinumab |
Synonyms ![]() |
CNTO-1275 | L04AC05 | Stelara® | TT-20 |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 172 |
Other databases | |
GtoPdb PubChem SID | 178103467 |
PubChem SID | 178103467 |
Search PubMed clinical trials | ustekinumab |
Search PubMed titles | ustekinumab |
Search PubMed titles/abstracts | ustekinumab |
Wikipedia | Ustekinumab |